More on Pharmacyclics (PCYC): FQ2 beats on both sales and EPS expectations. Revenue for the...

|By:, SA News Editor

More on Pharmacyclics (PCYC): FQ2 beats on both sales and EPS expectations. Revenue for the quarter consisted primarily of $50M in milestone revenue due to hitting a clinical milestone in connection with it's collaboration and license agreement with Janssen Biotech, plus $5M of license revenue related to its license agreement with Novo Nordisk under which Novo acquired exclusive worldwide rights to its small molecule Factor VIIa inhibitor, PCI-27483, for a restricted disease indication outside of oncology.